ARIAD Pharmaceuticals
edit

ARIAD is a Cambridge, Massachusetts-based biotechnology company focused on cancer. We are a cohesive team of talented people from diverse backgrounds with a shared vision: We seek to transform the lives of patients with breakthrough cancer medicines. This is our purpose. This is our passion. This is our promise.

Recent Milestones
edit

ARIAD Pharmaceuticals — Ariad gets $25M milestone payment from Merck (8/18/11)

Posted 8/18/11 at 5:36pm via masshightech.com
ARIAD Pharmaceuticals — the pivotal Phase 3 safety and efficacy trial of ridaforolimus, its drug candidate for metastatic soft-tissue or bone sarcomas, met its primary endpoint (1/18/11)

Posted 1/19/11 at 8:56am via masshightech.com
ARIAD Pharmaceuticals — announced a stock offering to help fund tests on a treatment for chronic myeloid leukemia, while also reporting that a Phase 2 study of its treatment for endometrial cancer showed significant improvements in progression-free survival (10/26/10)

Posted 10/26/10 at 6:43am via masshightech.com
Went public with stock symbol NASDAQ:ARIA.

Posted 8/18/11 at 5:37pm
ARIAD Pharmaceuticals added Larry Bock as Co-Founder.

Posted 8/30/10 at 1:32pm